GR852217B - - Google Patents

Info

Publication number
GR852217B
GR852217B GR852217A GR850102217A GR852217B GR 852217 B GR852217 B GR 852217B GR 852217 A GR852217 A GR 852217A GR 850102217 A GR850102217 A GR 850102217A GR 852217 B GR852217 B GR 852217B
Authority
GR
Greece
Application number
GR852217A
Other languages
Greek (el)
Inventor
John Walter Frank Goers
Chyi Lee
Richard Charles Siegel
Thomas Joseph Mickearn
Hurley Dalton King
Daniel James Coughlin
John Dennis Rodwell
Vernon Leon Alvarez
Original Assignee
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/650,375 external-priority patent/US4867973A/en
Application filed by Cytogen Corp filed Critical Cytogen Corp
Publication of GR852217B publication Critical patent/GR852217B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
GR852217A 1984-09-13 1985-09-12 GR852217B (US06373033-20020416-M00071.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65075484A 1984-09-13 1984-09-13
US06/650,375 US4867973A (en) 1984-08-31 1984-09-13 Antibody-therapeutic agent conjugates

Publications (1)

Publication Number Publication Date
GR852217B true GR852217B (US06373033-20020416-M00071.png) 1986-01-14

Family

ID=27095841

Family Applications (1)

Application Number Title Priority Date Filing Date
GR852217A GR852217B (US06373033-20020416-M00071.png) 1984-09-13 1985-09-12

Country Status (7)

Country Link
EP (1) EP0175617B1 (US06373033-20020416-M00071.png)
AU (2) AU583854B2 (US06373033-20020416-M00071.png)
CA (1) CA1326834C (US06373033-20020416-M00071.png)
DE (1) DE3584559D1 (US06373033-20020416-M00071.png)
DK (1) DK218386A (US06373033-20020416-M00071.png)
GR (1) GR852217B (US06373033-20020416-M00071.png)
WO (1) WO1986001720A1 (US06373033-20020416-M00071.png)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
GB8628398D0 (en) * 1986-11-27 1986-12-31 Central Blood Lab Authority Pharmaceutically-active conjugates
US4835258A (en) * 1986-12-24 1989-05-30 Northwestsern University Conjugation of aromatic amines or nitro-containing compounds with proteins or polypeptides by photoirradiation of the azide derivatives with ultraviolet light in order to produce antibodies against the haptens
JPH01502118A (ja) * 1987-01-15 1989-07-27 セルテク・リミテツド チオール反応性架橋剤
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
FR2610198B1 (fr) * 1987-02-03 1990-06-15 Ire Celltarg Sa Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant
FR2611141B1 (fr) * 1987-02-20 1991-02-01 Int Rech Cancer Centre Ensemble ou kit pour utilisation comme agent pour la destruction selective de cellules transformees ou tumorales
EP0282057A3 (en) * 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
US4937183A (en) * 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
EP0336383A3 (en) * 1988-04-07 1990-08-16 Takeda Chemical Industries, Ltd. Novel recombinant human lymphotoxin
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
USRE39094E1 (en) 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
DE3827940A1 (de) * 1988-08-13 1990-03-01 Schering Ag 13,17-propionsaeure- und propionsaeurederivat- substituierte porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
JPH04504248A (ja) * 1988-09-30 1992-07-30 ネオロクス　コーポレーション シッフ塩基で結合した、ターゲティング物質―診断／治療薬複合体
GR890100827A (el) * 1988-12-21 1991-03-15 Abbott Lab Μέ?οδος παραγωγής παραγώγων τετραπεπτιδίων ως ανταγωνιστών CCK.
US5270302A (en) * 1988-12-21 1993-12-14 Abbott Laboratories Derivatives of tetrapeptides as CCK agonists
WO1990015059A1 (en) * 1989-06-07 1990-12-13 The University Of British Columbia Photosensitizing diels-alder porphyrin derivatives
US5308608A (en) * 1989-06-07 1994-05-03 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
AU5732290A (en) * 1989-06-30 1991-01-17 Brunswick Corporation Antibody-oxidase conjugates with non-systemic substrates
CA2069439A1 (en) * 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
KR100208957B1 (ko) * 1990-04-25 1999-07-15 로렌스 티. 마이젠헬더 신규한 cc-1065 유사체
EP0553116A1 (en) * 1990-10-05 1993-08-04 Queen's University At Kingston Porphyrin derivatives
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
WO1997033620A2 (de) * 1996-03-15 1997-09-18 Pulsion Verw. Gmbh & Co. Medical Systems Kg Verbindungen zur behandlung von tumoren
US7390668B2 (en) 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US6493570B1 (en) * 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
ITRM960808A1 (it) * 1996-11-26 1998-05-26 Rossolini Gianmaria Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US7648695B2 (en) * 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
EP1210078B1 (en) * 1999-08-13 2008-08-27 Provectus Pharmatech, Inc. Improved topical medicaments and methods for photodynamic treatment of disease
WO2005014035A2 (en) * 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
US20070258993A1 (en) * 2003-11-12 2007-11-08 The Austin Research Institute Dna-Carrier Conjugate
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
EP2380909A1 (en) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
ES2874884T3 (es) 2014-02-21 2021-11-05 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Compuestos terapéuticos dirigidos a la glucosa
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019136335A1 (en) * 2018-01-05 2019-07-11 Gencyte Therapeutics, Inc. Precision molecular adaptor system for car-t immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970521A (en) * 1974-08-07 1976-07-20 Exxon Research And Engineering Company Immobilized glycoenzymes
CA1083508A (fr) * 1975-11-13 1980-08-12 Jacques Grange Supports porteurs de chaines laterales, procedes d'obtention de ces supports, procedes de fixation de composes organiques comportant un residu glucidique sur lesdits supports, produits et reactifs resultant de ladite fixation chimique
JPS52141882A (en) * 1976-05-20 1977-11-26 Hidetoshi Tsuchida Highhpolymeric complex of covalent type
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates

Also Published As

Publication number Publication date
EP0175617A2 (en) 1986-03-26
AU3016189A (en) 1989-07-13
EP0175617A3 (en) 1988-06-15
CA1326834C (en) 1994-02-08
DE3584559D1 (de) 1991-12-05
DK218386A (da) 1986-07-11
AU4807185A (en) 1986-04-08
AU583854B2 (en) 1989-05-11
DK218386D0 (da) 1986-05-12
EP0175617B1 (en) 1991-10-30
WO1986001720A1 (en) 1986-03-27

Similar Documents

Publication Publication Date Title
GR852217B (US06373033-20020416-M00071.png)
GR851225B (US06373033-20020416-M00071.png)
AT379850B (US06373033-20020416-M00071.png)
GR852299B (US06373033-20020416-M00071.png)
IN161398B (US06373033-20020416-M00071.png)
GR76573B (US06373033-20020416-M00071.png)
GR75574B (US06373033-20020416-M00071.png)
IN160841B (US06373033-20020416-M00071.png)
AU2219783A (US06373033-20020416-M00071.png)
IN160652B (US06373033-20020416-M00071.png)
AU2557584A (US06373033-20020416-M00071.png)
IN160392B (US06373033-20020416-M00071.png)
IN161539B (US06373033-20020416-M00071.png)
GR75561B (US06373033-20020416-M00071.png)
BG45163A1 (US06373033-20020416-M00071.png)
BG45254A1 (US06373033-20020416-M00071.png)
BG38294A1 (US06373033-20020416-M00071.png)
BG44737A1 (US06373033-20020416-M00071.png)
BG39778A1 (US06373033-20020416-M00071.png)
BG44749A1 (US06373033-20020416-M00071.png)
BG44718A1 (US06373033-20020416-M00071.png)
BG44806A1 (US06373033-20020416-M00071.png)
BG44829A1 (US06373033-20020416-M00071.png)
BG45025A1 (US06373033-20020416-M00071.png)
BG45054A1 (US06373033-20020416-M00071.png)